ABBV241122P197500
- 27.14
- 0.000.00%
AbbVie Newsroom
Aldeyra Therapeutics' Resubmitted Marketing Application for Eye Disease Drug Accepted by FDA
AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer
Where Will AbbVie Be in 5 Years?
Wells Fargo Maintains AbbVie(ABBV.US) With Buy Rating, Cuts Target Price to $195
AbbVie Snaps Eight Straight Sessions of Losses
S&P Sees Some Signs of a US Credit Bubble as Spreads Tighten
Monday Market Slow but Steady, Trump Buying Crypto Firm | Wall Street Today
Monday Opens to S&P 500 Climb, Dow Slides as Eyes Look Toward Nvidia | Live Stock
Wells Fargo Adjusts Price Target on AbbVie to $195 From $205, Maintains Overweight Rating
Aldeyra Says FDA Accepts Reproxalap NDA, AbbVie Deal Expanded to $100M
Express News | Aldeyra Therapeutics: Will Initiate Certain Pre-Commercial Activities, 60% of Which Will Be Paid by Abbvie, 40% by Co if Option Is Exercised
Express News | Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands Abbvie Option Agreement
Express News | RPT-Buzz-U.S. Stocks Weekly: Dunked
AbbVie Receives EC Approval of Elahere
Express News | Abbvie Receives European Commission Approval of Elahere® (Mirvetuximab Soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
AbbVie Receives European Commission Approval of ELAHERE (Mirvetuximab Soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices With Allergan Aesthetics Products
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year
Large Pension Doubled Palantir Stake, Bought Up Intel and CVS Stock